ICU Medical (ICUI) Projected to Post Quarterly Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is projected to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect ICU Medical to post earnings of $1.78 per share and revenue of $520.5660 million for the quarter. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The company had revenue of $535.94 million for the quarter, compared to the consensus estimate of $541.20 million. During the same quarter in the previous year, the firm earned $2.11 EPS. ICU Medical’s revenue was down 14.1% compared to the same quarter last year. On average, analysts expect ICU Medical to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

ICU Medical Trading Down 1.2%

Shares of ICU Medical stock opened at $117.22 on Wednesday. The firm’s 50 day simple moving average is $130.16 and its two-hundred day simple moving average is $138.29. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of 5,863.93, a PEG ratio of 1.71 and a beta of 0.74. ICU Medical has a 12-month low of $107.00 and a 12-month high of $160.29. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds have recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its position in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares in the last quarter. Headlands Technologies LLC acquired a new stake in ICU Medical in the 2nd quarter valued at about $177,000. O Shaughnessy Asset Management LLC acquired a new position in shares of ICU Medical during the 4th quarter worth approximately $203,000. Panagora Asset Management Inc. purchased a new stake in shares of ICU Medical in the fourth quarter valued at approximately $205,000. Finally, Janney Montgomery Scott LLC purchased a new position in ICU Medical during the fourth quarter worth approximately $216,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wall Street Zen downgraded ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Piper Sandler reduced their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, KeyCorp dropped their target price on ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $169.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.